
UPB Stock Forecast & Price Target
UPB Analyst Ratings
Bulls say
Upstream Bio is attractive because verekitug has already delivered clinically meaningful Phase 2 efficacy in severe asthma and CRSwNP, including a 56% reduction in annualized asthma exacerbations at 100mg every 12 weeks and strong nasal polyp and congestion improvements, while preserving a favorable safety and tolerability profile. Management has also achieved key clinical, regulatory, and manufacturing milestones ahead of planned Phase 3 initiation in 1Q27, and the company’s $207.4 million of cash and equivalents is expected to fund operations through 2027, reducing near-term financing pressure. The investment case is further strengthened by verekitug’s differentiated quarterly dosing versus monthly or more frequent competitor biologics and by additional upside from the fully enrolled 481-patient COPD trial, with data expected in 2H27.
Bears say
Upstream Bio is viewed negatively because its limited cash runway and the capital intensity of advancing pivotal asthma and CRSwNP programs create a financing overhang, with management expecting cash to fund operations through 2027 but not enough to complete both Phase 3 trials without a substantial equity raise in 2H27. The company also faces heightened execution and clinical risk after the market’s reaction to the February 11, 2026 Phase 2 VALIANT data, when the stock fell about 70% from February 10, 2026 to February 17, 2026 despite positive topline results, signaling investor concern about durability and dose consistency. Fundamentally, verekitug must still prove it can compete in severe asthma, CRSwNP, and COPD while overcoming regulatory, competitive, IP, and pricing pressures, and the need to raise capital at a higher discount rate increases dilution risk and reduces shareholder value.
This aggregate rating is based on analysts' research of Upstream Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
UPB Analyst Forecast & Price Prediction
Start investing in UPB
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Upstream Bio Inc (UPB) Forecast
UPB Analyst Forecast & Price Prediction
Start investing in UPB
Order type
Buy in
Order amount
Est. shares
0 shares